Wen Tao
About Wen Tao
Wen Tao is a director of NVFY (now XMax Inc.) appointed on September 23, 2025; she serves on the Audit, Compensation, and Nominating & Corporate Governance Committees. She is 35 and has been Director and Head of Institutional Sales at Alpha Trade Pty Ltd since January 2023; prior roles include APAC institutional sales at Saxo Bank (2019–2022) and Head of APAC Institutional Sales at Invast Financial Services (2016–2018). She is studying a part-time MBA at the University of Sydney and holds an ASIC RG 146 compliance certificate .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Alpha Trade Pty Ltd (Sydney/Malaysia) | Director & Head of Institutional Sales | Jan 2023 – present | Institutional sales leadership; Prime of Prime brokerage |
| Saxo Bank A/S (Singapore) | Institutional Sales (APAC) | Feb 2019 – Dec 2022 | APAC institutional coverage |
| Invast Financial Services (Sydney) | Head of APAC Institutional Sales | Feb 2016 – Oct 2018 | Regional sales leadership |
External Roles
| Type | Entity | Role | Tenure |
|---|---|---|---|
| Education | University of Sydney | MBA (part-time) | Since 2017 |
| Certification | ASIC RG 146 | Compliance Certificate | Not dated |
| Public company directorships | — | None disclosed in appointment filing | — |
Board Governance
- Committee memberships: Audit Committee; Compensation Committee; Nominating & Corporate Governance Committee (appointed Sept 23, 2025) .
- Appointment date and current service: Appointed to Board Sept 23, 2025 .
- Independence: Company policy (2024 proxy) states all members of Audit, Compensation, and Nominating committees are independent under Nasdaq rules; audit committee financial expert designation applies at the time to Umesh Patel. Wen Tao’s appointment to these committees aligns with the independence framework, though her independence status is not explicitly stated in filings .
- Attendance: Not disclosed in 2025 special proxy or 8‑Ks focused on her appointment .
Fixed Compensation
| Component | Amount/Terms | Source |
|---|---|---|
| Monthly director & committee fee | $1,880 per month | Director Agreement, Sept 23, 2025 |
| Expense reimbursement | Reasonable travel and out‑of‑pocket expenses | Director Agreement |
| Agreement termination | Either party may terminate on 30 days’ notice | Director Agreement |
| Confidentiality/non‑disclosure | 5 years post‑expiration | Director Agreement |
| Non‑compete | 1 year post‑expiration; excludes holdings <5% | Director Agreement |
Performance Compensation
| Element | Details | Source |
|---|---|---|
| Equity awards (RSUs/options) | None disclosed for Wen Tao | Appointment 8‑K and special proxy do not list any grants for Wen Tao |
| Performance metrics tied to pay | Not disclosed for directors | 2024 proxy outlines equity plan mechanics but no director‑specific performance pay |
Other Directorships & Interlocks
| Category | Entity | Note |
|---|---|---|
| Public company boards | — | None disclosed for Wen Tao in appointment 8‑K |
| Interlocks/potential conflicts | Alpha Trade Pty Ltd; prior Saxo/Invast roles | No related‑party transactions disclosed involving Wen Tao; company related‑party items involve CEO arrangements only |
Expertise & Qualifications
- Institutional sales leadership across APAC (Prime of Prime brokerage; European investment banking; Australian financial services) .
- Finance/accounting background (Bachelor of Commerce, Accounting & Finance; ASIC RG 146) .
- Ongoing MBA studies (University of Sydney) .
Equity Ownership
| Metric | As of | Value | Source |
|---|---|---|---|
| Shares outstanding | Oct 2, 2025 | 34,240,873 | Special proxy ownership section |
| Wen Tao beneficial ownership | Oct 2, 2025 | No shares reported | Special proxy table lists “Wen Tao, Director” with “–” (not reported), implying no beneficial ownership at that date |
Insider Trades
| Period Checked | Person | Result | Method |
|---|---|---|---|
| 2023‑01‑01 to 2025‑11‑20 | Wen Tao | No Form 4 transactions found | insider‑trades skill query (filing date field) – tool returned “No insider trades found” |
Governance Assessment
- Strengths: Broad committee coverage (Audit, Compensation, Nominating) suggests active oversight responsibilities; confidentiality and non‑compete covenants in the Director Agreement reinforce duty of loyalty and mitigate external conflicts .
- Alignment concerns: No beneficial ownership reported as of Oct 2, 2025; cash‑only monthly fee ($1,880) with no disclosed equity grants may limit alignment with shareholder outcomes relative to peers who utilize equity retainers; consider monitoring future proxy for any equity adoption .
- Potential red flags at board level: The Board sought approval to increase authorized shares from 250,000,000 to 5,000,000,000 and change company name—dilution and anti‑takeover considerations were explicitly disclosed by the company; while not specific to Wen Tao, such actions can affect investor confidence in governance. Continued oversight of issuance practices and dilution is warranted .
- Independence/attendance: Company policy requires committee members to be independent; Wen Tao’s committee roles align with that framework but filings do not explicitly state her independence nor provide attendance for 2025; watch the 2026 annual proxy for formal independence affirmation and attendance metrics .